U.S. Food Stock News

NasdaqGS:JJSF
NasdaqGS:JJSFFood

Is J&J Snack Foods (JJSF) Price Drop Creating A Potential Value Opportunity?

If you are wondering whether J&J Snack Foods is priced fairly right now or offering value at a discount, this article will walk through what the numbers are actually saying. The stock recently closed at US$84.87, with returns of 3.1% over 7 days, a 12.6% decline over 30 days, a 6.2% decline year to date, and a 30.0% decline over 1 year. These moves can change how the market views both its growth potential and risk. Recent coverage of J&J Snack Foods has focused on its role in the frozen and...
NYSE:OII
NYSE:OIIEnergy Services

Does Strong 2025 Earnings and Buybacks Change The Bull Case For Oceaneering International (OII)?

In the fourth quarter and full year ended December 31, 2025, Oceaneering International reported sales of US$668.57 million and US$2.78 billion, respectively, with quarterly net income rising to US$177.65 million and full-year net income reaching US$353.76 million, alongside higher diluted EPS from continuing operations versus the prior year. An interesting aspect of these results is that Oceaneering expanded profit significantly even as fourth-quarter revenue declined year over year,...
NasdaqGS:FISV
NasdaqGS:FISVDiversified Financial

Jana Push At Fiserv Tests Turnaround Story And Portfolio Focus

Jana Partners has built a significant stake in Fiserv and is publicly pushing for operational and governance changes. The activist investor is calling for a review of non core businesses and potential board refreshment. Jana has voiced support for CEO Mike Lyons' ongoing turnaround efforts while urging a fresh look at the company's structure. For existing and potential shareholders in NasdaqGS:FISV, this intervention comes after a mixed share price record. The stock closed at $63.01, with a...
NYSE:EQR
NYSE:EQRResidential REITs

Does EQR’s 2026 EPS Outlook and Near-Complete Buyback Shift the Bull Case for Equity Residential?

In early February 2026, Equity Residential reported its fourth-quarter and full-year 2025 results, showing higher annual sales and earnings, issued first-quarter and full-year 2026 EPS guidance of US$0.29–US$0.33 and US$1.44–US$1.56 respectively, and disclosed that it has repurchased 3,400,000 shares for US$205.7 million under a long-running buyback program. The combination of growing full-year 2025 earnings and continued buybacks, with more than 98% of the authorized repurchase plan now...
NasdaqGS:EXE
NasdaqGS:EXEOil and Gas

A Look At Expand Energy’s Valuation As Earnings Beat And 2026 Outlook Highlight Growth And Capital Returns

Expand Energy (EXE) just delivered quarterly earnings and revenue above analyst expectations, supported by higher production, stronger cash flow and lower breakeven costs in its Haynesville operations, alongside new 2026 production and capital allocation plans. See our latest analysis for Expand Energy. Despite the earnings beat and updated 2026 production plans, the share price has eased recently, with a 90 day share price return of 13.08% and a year to date share price decline of 9.34%,...
NYSE:IDA
NYSE:IDAElectric Utilities

How Investors May Respond To IDACORP (IDA) Landing Aristotle Capital Boston’s Vote of Confidence

IDACORP recently drew fresh attention after Aristotle Capital Boston added the Idaho-based electric utility to its portfolio, praising strong industrial load growth, regional transmission opportunities, and a robust five-year capital investment plan. The asset manager’s emphasis on constructive regulation, expanding rate base, and long-term earnings potential has sharpened investor focus on IDACORP’s growth and infrastructure story ahead of its Q4 2025 results release and earnings call held...
NasdaqGS:DFTX
NasdaqGS:DFTXPharmaceuticals

Jefferies’ DT120 Confidence and Psychedelic Tailwinds Might Change The Case For Investing In Definium Therapeutics (DFTX)

Jefferies recently began covering Definium Therapeutics, highlighting Phase IIb data showing a single dose of lead candidate DT120 achieved a 48% remission rate in generalized anxiety disorder and assigning strong confidence in its upcoming Phase III trials. At the same time, strong late-stage results and regulatory progress for COMP360 at Compass Pathways have lifted sentiment across the psychedelics space, indirectly enhancing investor attention on Definium’s clinical pipeline. Next, we’ll...
NasdaqGS:ANDE
NasdaqGS:ANDEConsumer Retailing

Andersons (ANDE) Thin 0.9% Net Margin Reinforces Bearish Low Profitability Narrative

Andersons (ANDE) has just wrapped up FY 2025 with fourth quarter revenue of US$2.5 billion, basic EPS of US$1.98 and net income of US$67.4 million. Trailing twelve month revenue came in at about US$11.0 billion with EPS of US$2.81. Over recent quarters the company has seen quarterly revenue move between US$2.5 billion and US$3.1 billion, with EPS ranging from close to flat at US$0.01 in Q1 2025 to US$1.98 in Q4. This creates a backdrop where modest net profit margins and small shifts in...
NYSE:MSM
NYSE:MSMTrade Distributors

How JP Morgan’s Downgrade And Self‑Help Concerns At MSC Industrial Direct (MSM) Has Changed Its Investment Story

On February 6, 2026, JP Morgan downgraded MSC Industrial Direct to Neutral, expressing concern that its self-help initiatives have not delivered clear operational benefits. Just weeks earlier, shareholders had strongly re-elected all ten directors, highlighting solid support for the same management team now facing renewed scrutiny over execution. Next, we will examine how JP Morgan’s concern over MSC’s self-help efforts could influence the company’s existing investment narrative. The...
NYSE:RMD
NYSE:RMDMedical Equipment

A Look At ResMed (RMD) Valuation After Robust Q2 Beat And Upgraded Analyst Outlook

ResMed (RMD) is back in focus after a strong fiscal Q2, where its Masks & Accessories and Devices businesses outperformed expectations and analysts responded by lifting their financial outlook and maintaining positive coverage. See our latest analysis for ResMed. ResMed’s share price has moved to US$258.91, with a 6.15% 90 day share price return and a 1 year total shareholder return of 11.4%. This suggests momentum has been building around its recent Q2 beat and margin guidance. If this Q2...
NasdaqGS:UAL
NasdaqGS:UALAirlines

United Airlines (UAL) Valuation Check After Major GEnx Engine Order And Expanded Starlink Partnership

United Airlines Holdings (UAL) is back in focus after committing to 300 GE Aerospace GEnx engines for its Boeing 787 Dreamliners and widening its Starlink partnership, a twin move centered on fleet efficiency and passenger connectivity. See our latest analysis for United Airlines Holdings. These engine and connectivity commitments come after a busy few weeks, with United agreeing to invest $100 million in Azul S.A., bidding $30.2 million for Spirit’s O’Hare gates, and preparing to present at...
NYSE:SM
NYSE:SMOil and Gas

Is SM Energy (SM) Pricing Reflect Its Volatile Share Performance And Earnings Multiple Today

If you are wondering whether SM Energy's current share price lines up with its underlying value, you are not alone. This article is built to help you frame that question clearly. Over the short term the stock has been volatile, with a 6.8% move over 7 days, 28.5% over 30 days and 22.3% year to date, while the 1-year return sits at a 37.5% decline and the 5-year return at 73.7%. These swings have come alongside ongoing attention on US onshore oil and gas producers and how they are positioned...
NYSE:HCC
NYSE:HCCMetals and Mining

Record Blue Creek Ramp And Higher 2026 Output Guidance Might Change The Case For Investing In Warrior Met Coal (HCC)

Warrior Met Coal, Inc. reported past fourth-quarter 2025 results showing steelmaking coal production rising to 3,392,000 short tons, including 1.3 million short tons from the newly producing Blue Creek mine, alongside higher quarterly revenue and net income versus a year earlier. Despite full-year 2025 revenue and earnings being lower than the prior year, record output and the early, low-cost ramp-up at Blue Creek underpinned stronger margins in late 2025 and supported the company’s higher...
NasdaqGM:CRSP
NasdaqGM:CRSPBiotechs

Casgevy Adoption And Pipeline Progress Reshape CRISPR Therapeutics Investment Story

CRISPR Therapeutics (NasdaqGM:CRSP) is seeing wider use of its gene editing therapy Casgevy, with more patients starting treatment and broader reimbursement access in the U.S. and abroad. The company is reporting progress across its in vivo editing programs and siRNA pipeline, signaling activity beyond its core hematology focus. These updates point to shifting business fundamentals for CRISPR Therapeutics that have not yet been discussed in our prior coverage. CRISPR Therapeutics focuses on...
NYSE:DIN
NYSE:DINHospitality

February 2026's Undervalued Small Caps With Insider Actions To Consider

As February 2026 begins, U.S. stock markets have shown resilience with major indices like the Dow Jones and S&P 500 ending sharply higher, buoyed by positive economic indicators such as an unexpected expansion in factory activity. In this dynamic environment, small-cap stocks present intriguing opportunities for investors seeking value and growth potential, especially when insider actions suggest confidence in a company's prospects amidst broader market optimism.
NasdaqGS:ROKU
NasdaqGS:ROKUEntertainment

Exploring 3 High Growth Tech Stocks in the US Market

As February begins, the U.S. stock market has shown strength with major indices like the Dow Jones and S&P 500 posting significant gains, signaling a positive start to the month despite ongoing economic uncertainties and geopolitical developments. In this environment, high-growth tech stocks in the U.S. market continue to attract attention for their potential to leverage technological advancements and shifting consumer demands, making them noteworthy considerations for investors looking to...
NasdaqGS:CSGP
NasdaqGS:CSGPReal Estate

3 Stocks That May Be Trading Below Estimated Value In February 2026

As February 2026 begins, the U.S. stock market shows a robust start with major indices like the Dow Jones Industrial Average and S&P 500 posting significant gains. In this environment of renewed optimism, identifying stocks that may be trading below their estimated value can offer intriguing opportunities for investors looking to capitalize on potential growth amid favorable market conditions.
NasdaqGS:TSLA
NasdaqGS:TSLAAuto

Latest News In Energy Transition - Hydrogen Infrastructure Growth Driven By Global Decarbonization Policies

Global decarbonization policies and subsidies are major drivers of the hydrogen infrastructure market, fostering demand for pipelines, storage, and refueling networks. Key initiatives like the US Inflation Reduction Act and EU plans such as REPowerEU are creating a policy "floor" that lowers investment risks and encourages the advancement of hydrogen infrastructure as part of the broader energy transition. This growing focus on building large-scale hydrogen infrastructure is supported by...
NasdaqGS:IBRX
NasdaqGS:IBRXBiotechs

Insiders Favor These 3 Leading Growth Companies

As February begins, U.S. stock markets are showing strong momentum, with major indexes like the Dow Jones Industrial Average and S&P 500 posting significant gains. In this environment of market optimism, investors often look for growth companies with high insider ownership as an indicator of confidence and potential resilience amidst economic shifts.
NasdaqGS:AUTL
NasdaqGS:AUTLBiotechs

Spotlight On Silence Therapeutics And 2 Other Promising Penny Stocks

As February begins, the U.S. stock market is showing strength, with major indexes like the Dow Jones and S&P 500 posting significant gains. In this context of rising indices, investors often look for opportunities that may offer growth potential at a lower entry cost. Penny stocks, though considered a niche investment area today, still hold promise by offering access to smaller or newer companies that can potentially deliver strong returns when backed by solid financials. Let's explore...